UNIDOSE PHARMA
ActiveUNIDOSE PHARMA has been active since 1999 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €889k and a net result of €224k. Equity remains stable across the filed fiscal years (±1.4% per year). Its solvency ranks better than 33% of 10359 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.6% (low).
Checked score
Score 2025
62
/ 100
Healthy
The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability76▼-9
Solvency48▲+5
Growth78=
Track record100
Bankruptcy probability, 12 months
0.6%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €55k at 30 days acceptable
Liquidity tight (current ratio 1.17 against 1.05 in 2024; short-term debt: 41.2% and cash: 2.8% of total assets), and 77.2% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Eight signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
22.8%
Return on assets
5.7%
Age of the figures
9 mo
lowers risk · Growing equity
Reported equity is higher than in 2023 and did not fall compared with 2024. These amounts do not establish the cause of the change.
NBB · annual accounts 2025Equity per financial year
1819202122232425
2018 to 2025 · latest year €889k
neutral · Filed after the deadline
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 31-08-2026, 31 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 10 filingsDeviation from the deadline
2025
31 d late
2024
29 d late
2023
30 d late
2022
30 d late
2021
40 d early
2020
59 d early
2019
36 d early
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
23-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, abbreviated schema
Equity
€889k▲ 33.6%
2024 · €666k
2018: €561k
2019: €519k
2020: €398k
2021: €432k
2022: €233k
2023: €202k
2024: €666k
2018 → 2025
Total assets
€3.90M▲ 7.9%
2024 · €3.62M
2018: €1.48M
2019: €1.60M
2020: €1.37M
2021: €1.14M
2022: €3.48M
2023: €3.68M
2024: €3.62M
2018 → 2025
Net result
€224k▼ 51.7%
2024 · €463k
2018: €55k
2019: €-42k
2020: €-121k
2021: €35k
2022: €-200k
2023: €-30k
2024: €463k
2018 → 2025
Working capital
€275k▲ 314%
2024 · €67k
2018: €186k
2019: €108k
2020: €642
2021: €42k
2022: €-249k
2023: €-604k
2024: €67k
2018 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€432k-€233k▼ 46.2%€202k▼ 13.0%€666k▲ 229%€889k▲ 33.6%
Operating result€43k-€-184k€40k€599k▲ 1,391%€360k▼ 39.8%
Net result€35k-€-200k€-30k▲ 84.8%€463k€224k▼ 51.7%
Turnover and EBIT margin not published: the abbreviated schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result falls in 2025; 2025 is 40% below 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €3.90M
Fixed assets
€2.02M▼ 5.1%
Current assets
€1.88M▲ 26.4%
Equity and liabilities €3.90M
Equity
€889k▲ 33.6%
Provisions
€56k▼ 5.6%
Debt
€2.96M▲ 2.2%
The debt ratio falls from 80.0% to 75.8%. Equity and debt are higher.
Key figures and ratios
EBITDA
€554k▼
2024 · €788k
Cash flow
€417k▼
2024 · €652k
Solvency
22.8%▲
2024 · 18.4%
Current ratio
1.17▲
2024 · 1.05
Quick ratio
0.80▲
2024 · 0.61
Debt / equity
3.33▼
2024 · 4.35
ROE
25.1%▼
2024 · 69.6%
ROA
5.7%▼
2024 · 12.8%
Interest coverage
8.27▼
2024 · 9.19
Debt
€2.96M▲
2024 · €2.90M
Debt ≤ 1 year
€1.61M▲
2024 · €1.42M
Debt > 1 year
€1.34M▼
2024 · €1.46M
Income taxes
€77k▲
2024 · €0
Staff costs
€1.10M▲
2024 · €999k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€3.62M€3.90M▲
Fixed assets21/28€2.13M€2.02M▼
Tangible fixed assets22/27€2.13M€2.02M▼
Land and buildings22€1.47M€1.47M▲
Plant, machinery and equipment23€635k€530k▼
Furniture and vehicles24€24k€16k▼
Current assets29/58€1.49M€1.88M▲
Stocks and contracts in progress3€629k€602k▼
Stocks30/36€629k€602k▼
Amounts receivable within one year40/41€606k€1.17M▲
Trade receivables40€453k€974k▲
Other amounts receivable41€153k€194k▲
Cash at bank and in hand54/58€245k€111k▼
Deferred charges and accrued income490/1€11k€4k▼
Equity and liabilities
Total equity and liabilities10/49€3.62M€3.90M▲
Equity10/15€666k€889k▲
Contributions10/11€370k€370k=
Reserves13€296k€520k▲
Tax-exempt reserves132€206k€196k▼
Distributable reserves133€90k€324k▲
Profit (loss) carried forward14€0-
Provisions and deferred taxes16€59k€56k▼
Deferred taxes168€59k€56k▼
Amounts payable17/49€2.90M€2.96M▲
Amounts payable after more than one year17€1.46M€1.34M▼
Financial debts170/4€1.46M€1.34M▼
Amounts payable within one year42/48€1.42M€1.61M▲
Current portion of amounts payable after more than one year42€124k€126k▲
Financial debts43€150k€0▼
Credit institutions430/8€150k€0▼
Trade debts44€354k€751k▲
Suppliers440/4€354k€751k▲
Taxes, remuneration and social security45€127k€217k▲
Taxes450/3€0€51k▲
Remuneration and social security454/9€127k€166k▲
Other amounts payable47/48€669k€516k▼
Accrued charges and deferred income492/3€8k€6k▼
Income statement
Code20242025
Non-recurring operating income76A€265k€0▼
Remuneration, social security and pensions62€999k€1.10M▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€189k€193k▲
Other operating charges640/8€15k€10k▼
Non-recurring operating charges66A€0-
Gross operating margin9900€1.80M€1.66M▼
Operating profit (loss)9901€599k€360k▼
Financial income75/76B€9k€4k▼
Recurring financial income75€9k€4k▼
Financial charges65/66B€86k€67k▼
Recurring financial charges65€86k€67k▼
Profit (loss) for the period before taxes9903€523k€297k▼
Transfer from deferred taxes780€7k€3k▼
Transfer to deferred taxes680€66k€0▼
Income taxes67/77€0€77k▲
Profit (loss) for the period9904€463k€224k▼
Transfer from tax-exempt reserves789€21k€10k▼
Transfer to tax-exempt reserves689€199k€0▼
Profit (loss) for the period to be appropriated9905€285k€234k▼
Appropriation of the result
Profit (loss) to be appropriated9906€-73k€234k▲
Profit (loss) brought forward from the previous period14P€-359k€0▲
Transfer from equity791/2€73k€0▼
Transfer to equity691/2-€234k
To other reserves6921-€234k
Social balance
Average headcount (FTE)908717.419.2▲
The notes to these accounts (22 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
31-08
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema · 31 days late
2025
29-08
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema · 29 days late
2024
31-12
Financial
Back to profitnet €463k
Net result €463k after 2 loss-making years.
31-12
Financial
Equity above €500kEq €666k ▲229%
Equity rises from €202k to €666k.
30-08
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema · 30 days late
2023
30-08
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema · 30 days late
2022
31-12
Financial
Weakest financial yearnet €-200k ▼677%
Net result drops to €-200k, the lowest in the series; recovery starts the following year.
21-06
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema
2021
31-12
Financial
Back to profitnet €35k
Net result €35k after 2 loss-making years.
02-06
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema
2020
25-06
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema
2019
09-07
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema
2018
30-08
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema · 30 days late
2017
09-06
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
5 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Izegem · 2 establishment units since 1999
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Kachtemsplein 108870 IzegemGround area
1,264 m²
Building footprint
935 m²
Volume, LiDAR
1,147 m³
2 parcels, Flanders · tallest building 10.9 m, ±2 floors. Linked by address, not a title deed.
2 establishment units
Apotheek Kachtem
since 19992.097.010.138
Unidose Pharma
since 20222.339.357.215
2 parcels
Flanders
2
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 44017D0567/00P002 | Flanders | 1,073 m² | 1 · 744 m² | - |
| 36009A0350/00R000 | Flanders | 191 m² | 1 · 191 m² | 10.9 m · 2 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1 · via establishment units: 1
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Recognitions · licences · registrations
Food safety, FASFC
1 siteIzegem2.097.010.138
Similar companies · same sector, comparable size
Vandewalle-Verrue
BE 0831.028.692
Vleteren · Eq €890k
XPHARMA
BE 0663.736.158
Puurs-Sint-Amands · Eq €890k
HULSPHARMA
BE 0435.910.080
Hulshout · Eq €890k
APOTHEEK FRANSEN
BE 0432.655.137
Hoogstraten · Eq €887k
EL RASS
BE 0426.283.623
Schaarbeek · Eq €892k
Of 5,222 companies in sector 47730 we hold annual accounts for 3,861. 3,101 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded15-11-1999
Fiscal year end31-12
Activities, NACEBEL
47730Retail sale of pharmaceutical products
52310
68201Renting and operating of own or leased residential real estate, excluding social housing
Sources
Crossroads Bank for EnterprisesNational Bank · 26 filingsAddress and cadastre registers
Data from official sources, last processed on 22-09-2026. Scores and ratios are computed by Checked and are not a credit decision.